Search on Site

Explore our comprehensive database of pharmaceutical news releases, press releases, events, and industry insights with ease. Effortlessly find relevant information tailored to your interests and stay updated on the latest developments in the pharmaceutical sector. Start searching now to uncover valuable insights and resources for your pharmaceutical endeavors.
Did you mean: ⟹ act date of 1?

Orthofix Receives FDA 510(k) Clearance for Rodeo™ Telescopic Nail

Orthofix Medical Inc. a leading global spine and orthopedics company, today announced that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance to market its Rodeo™ Telescopic Nail. The Rodeo Telescopic Nail is an innovative...

Regulus Therapeutics Progresses to Cohort 4 in Phase 1b MAD Trial of RGLS8429 for ADPKD Treatment

Regulus Therapeutics Inc. a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs today announced, after review of all available safety data, the Company initiated screening of the fourth...

Adcentrx Therapeutics: China NMPA Clears IND for ADRX-0706, a Novel Nectin-4 ADC in Advanced Solid Tumor Treatment

Adcentrx Therapeutics ("Adcentrx"), a biotechnology company revolutionizing Antibody-Drug Conjugate (ADC) therapeutics for cancer and other life-threatening diseases, announced that China National Medical Products Administration (NMPA) has cleared...

enGene to Showcase Pivotal Phase 1/2 LEGEND Study Details of EG-70 in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

enGene Holdings Inc. (Nasdaq: ENGN) or ("enGene" or the "Company"), a clinical-stage genetic medicines company whose non-viral lead program EG-70 is in a pivotal study for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), today...

Factor Bioscience to Deliver Seven Presentations at the American Society of Gene & Cell Therapy

Factor Bioscience Inc., a Cambridge-based biotechnology company focused on developing mRNA and cell-engineering technologies, announced its participation in the American Society of Gene & Cell Therapy. Factor will deliver seven presentations,...

SOPHiA GENETICS Announces Syndicate Bio as First Liquid Biopsy Customer in Africa

SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company in the healthcare space and a leader in data-driven medicine, announced that Nigeria-based Syndicate Bio has signed on to implement MSK-ACCESS® powered with SOPHiA DDM™. Platform, and...

Hyalex Orthopaedics Reports Treatment of First Patients with Novel HYALEX® Knee Cartilage System

Hyalex Orthopaedics, a privately held medical device company developing cartilage repair products based on the transformative HYALEX® materials platform, announced that patients have successfully received HYALEX Knee Implants as part of the...

ImmunityBio Announces FDA Approval of ANKTIVA®,

ImmunityBio, Inc. an immunotherapy company, today announced that the U.S. Food and Drug Administration (FDA) has approved ANKTIVA (N-803, or nogapendekin alfa inbakicept-pmln) plus Bacillus Calmette-Guérin (BCG) for the treatment of patients with...

Moleculin's AML treatment gets EMA's Orphan Drug Designation

Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, announced that the European Medicines Agency has...

Beckman Coulter's DxI 9000 Immunoassay Analyzer

Beckman Coulter Diagnostics, a leader in clinical diagnostics, announced ahead of the congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global), that it has extended the menu of DxI 9000 Immunoassay...

Scientific article highlights Namodenoson as promising for advanced liver cancer and MASH

Can-Fite BioPharma Ltd. a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, announced that Biomedicines published an article titled “Namodenoson at the Crossroad of...

Algiax Pharmaceuticals expands AP-325 study in chronic neuropathic pain, adds 12 sites in Belgium and France

Algiax Pharmaceuticals, today provided an update on its ongoing Phase 2a study (NCT04429919) with lead candidate AP-325 in patients with chronic neuropathic pain. Based on last year's positive mid-enrollment interim analysis and confirmed...

Kiromic BioPharma reports positive results from third patient in Deltacel-01 trial

Kiromic BioPharma, Inc. reports early efficacy results showing tumor stabilization in the third patient enrolled in the Company’s Deltacel-01 Phase 1 clinical trial. Deltacel-01 is evaluating Deltacel™ (KB-GDT-01), Kiromic’s allogeneic....

Sapience Therapeutics to Present Multiple Posters at the American Association for Cancer Research

Sapience Therapeutics, Inc., a clinical-stage biotechnology company focused on the discovery and development of peptide therapeutics to address oncogenic and immune dysregulation that drive cancer, announced three poster presentations at the 2024...

Tetra Pharm Technologies advances CB1 antagonist, TPT0701, for appetite suppression into preclinical testing

Following the successful filing of Intellectual Property (IP) for their applied platform technology targeting the endocannabinoid system (ECS), Tetra Pharm Technologies, is moving forward with its compound for appetite suppression, TPT0701....

Trailblazing 3D human liver models yield accurate MASH phenotype

Viscient Biosciences ("Viscient") announced that its scientists, along with collaborators from University of California, San Diego, Sanford-Burnham-Prebys medical research institute, and Salk Institute, have published the first demonstration of a...

CVS Pharmacy® announces new simplified loyalty experience

CVS Pharmacy®, the retail division of CVS Health® (NYSE: CVS), today announced the evolution of its loyalty program to include two membership tiers: ExtraCare® and ExtraCare Plus™. ExtraCare: The popular, no-fee loyalty program through which...

Editorial Guidelines | Pharmaceutical-Era.com

Editorial Guidelines At Pharmaceutical-Era.com, we strive to maintain the highest standards of quality and integrity in our editorial content. Our guidelines are designed to ensure that all articles, press releases, and other submissions are...

FAQs

Frequently Asked Questions (FAQs) What are the genuine benefits of using Pharmaceutical-Era.com for press release distribution or promotion? Pharmaceutical-Era.com offers unparalleled visibility to your press releases within the pharmaceutical...

Terms of Use | Pharmaceutical-Era.com - Understand Our Terms and Conditions

Terms Of Use — Terms & Conditions Welcome to Pharmaceutical-Era (referred to as "Pharmaceutical-Era," "we," "us," or "our"). By accessing or using our website (www.pharmaceutical-era.com), you agree to comply with and be bound by the following...